US2021161970A1PendingUtilityA1
Methods and uses of biological tissues for various stent and other medical applications
Est. expiryFeb 10, 2032(~5.6 yrs left)· nominal 20-yr term from priority
A61L 27/3683A61L 27/3604A61F 2/2418A61F 2/2415A61L 31/08A61F 2/2475A61K 35/42
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods and uses of biological tissues for various stent and other medical applications. In an exemplary embodiment of a method of processing a tissue of the present disclosure, the method comprises the steps of acquiring a mammalian tissue comprising at least a portion of a pulmonary region tissue, selecting a sample of pulmonary region tissue from the at least a portion of a pulmonary region tissue, and fixing the sample of pulmonary region tissue using a fixative, resulting in a fixed sample. In at least one embodiment, the step of selecting a sample of pulmonary region tissue comprises selecting a sample of pulmonary ligament tissue from the mammalian tissue.
Claims
exact text as granted — not AI-modified1 . A product, comprising:
a frame configured to retain a mammalian tissue thereon; and the mammalian tissue coupled to the frame; wherein when the product is positioned within a mammalian luminal organ, fluid native to the mammalian luminal organ may pass through a lumen defined within the product; wherein the product is configured as a stent valve; wherein the mammalian tissue comprises visceral pleura; and wherein the mammalian tissue is fixed.
2 . The product of claim 1 , wherein the mammalian tissue is chemically fixed.
3 . The product of claim 1 , wherein a segment of the mammalian tissue is decellularized.
4 . The product of claim 1 , wherein the visceral pleura is harvested from a middle-anterior portion of a lung.
5 . The product of claim 1 , wherein the mammalian tissue is fixed using a fixative selected from the group consisting of glutaraldehyde, formaldehyde, and glycerol.
6 . The product of claim 1 , wherein the mammalian tissue is fixed using a fixative within a HEPES or phosphate buffer.
7 . The product of claim 1 , wherein the mammalian tissue is fixed using a fixation procedure selected from the group consisting of aqueous fixation, cryo-preservation, and dry tissue fixation.
8 . The product of claim 1 , wherein the mammalian tissue is fixed using a fixative that is buffered.
9 . The product of claim 1 , wherein the mammalian tissue is sterilized.
10 . The product of claim 1 , wherein the stent valve is configured for use as a venous valve.
11 . The product of claim 1 , wherein the frame comprises a material selected from the group consisting of nitinol, chromium, cadmium, molybdenum, nickel, a nickel composite, nickel-cadmium nickel-chromium, nitinol palladium, palladium, cobalt, platinum, and stainless steel.
12 . A product, comprising:
a frame configured to retain a mammalian tissue thereon, the frame comprising a first end, a second end, a longitudinal axis, one or more lower arms, and at least one connection portion extending along the longitudinal axis, the one or more lower arms disposed at the second end and connected to the at least one connection portion, the at least one connection portion comprising connection bars; and the mammalian tissue coupled to the frame; wherein when the product is positioned within a mammalian luminal organ, fluid native to the mammalian luminal organ may pass through a lumen defined within the product; wherein the product is configured as a stent valve; wherein the mammalian tissue comprises visceral pleura; wherein the at least one connection portion is used to connect the visceral pleura to the frame; and wherein the mammalian tissue is fixed.
13 . The product of claim 12 , wherein the mammalian tissue is chemically fixed.
14 . The product of claim 12 , wherein a segment of the mammalian tissue is decellularized.
15 . The product of claim 12 , wherein the visceral pleura is harvested from a middle-anterior portion of a lung.
16 . The product of claim 12 , wherein the mammalian tissue is fixed using a fixative selected from the group consisting of glutaraldehyde, formaldehyde, and glycerol.
17 . The product of claim 12 , wherein the mammalian tissue is sterilized.
18 . The product of claim 12 , wherein the stent valve is configured for use as a venous valve.
19 . The product of claim 12 , wherein the frame comprises a material selected from the group consisting of nitinol, chromium, cadmium, molybdenum, nickel, a nickel composite, nickel-cadmium nickel-chromium, nitinol palladium, palladium, cobalt, platinum, and stainless steel.
20 . A product, comprising:
a frame configured to retain a mammalian tissue thereon, the frame comprising a first end, a second end, a longitudinal axis, one or more lower arms, and at least one connection portion extending along the longitudinal axis, the one or more lower arms disposed at the second end and connected to the at least one connection portion, the at least one connection portion comprising connection bars; and the mammalian tissue coupled to the frame; wherein when the product is positioned within a mammalian luminal organ, fluid native to the mammalian luminal organ may pass through a lumen defined within the product; wherein the product is configured as a bileaflet stent valve; wherein the mammalian tissue comprises visceral pleura; wherein the at least one connection portion is used to connect the visceral pleura to the frame; and wherein the mammalian tissue is fixed.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.